In addition to the effect in the signal transduction cascade, the capacity of nimotuzumab of increasing the proportion of T-lymphocytes recognizing HER1 (EGFR) peptides in vivo was assessed in subjects with SCCHN (59). Here, EGFR is linked to head and neck squamous cell carcinoma.